Gleevec Sales Gains May Come From Increased Dosing Compliance
This article was originally published in The Pink Sheet Daily
Novartis is hoping to boost sales of its oncologic Gleevec (imatinib) by increasing patient compliance with the daily dosing regimen
You may also be interested in...
Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.
Novartis is seeking to increase the maximum approved dose of its oncologic Gleevec (imatinib mesylate) to 800 mg, Oncology President David Epstein said Jan. 20
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications